Dianthus Therapeutics, Inc.

NasdaqCM:DNTH Stock Report

Market Cap: US$5.3b

Dianthus Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Dianthus Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-19.1%

Buyback Yield

Total Shareholder Yield-19.1%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Jun 17

Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued

Dianthus Therapeutics (DNTH) drew fresh attention after reporting positive midstage results from its CAPTIVATE Phase 3 trial in chronic inflammatory demyelinating polyneuropathy, highlighting a high confirmed responder rate along with a favorable safety profile. See our latest analysis for Dianthus Therapeutics. The CAPTIVATE data arrived after a strong run in Dianthus Therapeutics, with the share price at $78.88 and a year to date share price return of 98.79%. Short term momentum has cooled,...
Seeking Alpha • May 30

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Summary Dianthus Therapeutics is positioned as a category-expanding biotech, leveraging convenience and safety to address autoimmune neuromuscular and rheumatology markets. DNTH boasts a robust balance sheet with over $1 billion in cash and investments, ensuring operational runway through 2030 and strategic independence post-positive clinical data. Claseprubart’s promising efficacy and safety in gMG, CIDP, and MMN, alongside the DNTH212 rheumatology franchise, underpin a multi-pronged growth thesis with major catalysts in late 2026. Valuation is driven by optionality from a well-funded pipeline, but key risks remain in Phase 3 trial translation and competitive differentiation against established players. Read the full article on Seeking Alpha

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if DNTH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DNTH's dividend payments have been increasing.

Dividend Yield vs Market

Dianthus Therapeutics Dividend Yield vs Market
How does DNTH dividend yield compare to the market?
SegmentDividend Yield
Company (DNTH)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.3%
Analyst forecast (DNTH) (up to 3 years)n/a

Notable Dividend: Unable to evaluate DNTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DNTH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate DNTH's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DNTH has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 19:45
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dianthus Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Colleen KusyBaird
null nullBaird